A
Publicly Traded Venture Capital Company Investing in Tiny Technology |
||||
|
||||
SIX MONTHS' REPORT 2004 |
||||
|
||||
FELLOW SHAREHOLDERS: |
||||
|
||||
Our Company is the strongest
it has ever been. In making this
self-assessment, we are taking into account our position (within both the
venture capital and the nanotechnology communities), our management team, our
deal flow and our financial capacity. |
||||
|
||||
Our position as a leading
investor in privately held, tiny-technology enabled companies, particularly
those working at the nanoscale, is more and more established as time goes
by. We began making new investments
exclusively in tiny-technology companies in early 2001. Since then:
We have been one of the most active venture capital firms in tiny
technology, having made 16 such investments.
We have been hiring personnel appropriate for our task. No one who has been offered a job at our
Company has turned it down, and other than through retirement, we have had no
turnover of employees. We have a
well-qualified, hard-working team. Our
deal flow has never been more robust.
So far this year, we have seen on the order of 200 business
opportunities. Finally, our financial
capacity has never been greater. We
have more cash and equivalents (over $52 million at this writing), and a higher
ratio of cash and equivalents to total assets, than we have ever had. |
||||
|
||||
In summary, we have the
positioning, the people, the deal flow and the capital that we believe we
need in order to maintain, over at least the near term, our position as one of
the leading investors in tiny technology--especially nanotechnology--venture
capital opportunities. Longer term, in
order to maintain our relative position, we will have to increase both our
employee roster and our capital base, as we expect nanotechnology in
particular to become one of the most active and capital intensive recipients
of venture capital funding. Ideally,
at some point we would like not to raise additional capital, but rather to
finance our growth internally, as we are permitted to pay a 35 percent
corporate income tax and retain 65 percent of our net realized long-term
capital gains with a comparable credit for our shareholders against their
taxes. (Shareholders should read the
section of our Annual Report entitled, "Subchapter M Status," to
understand the tax benefits for which they are eligible when we pay income
taxes on realized long-term capital gains.)
|
||||
|
||||
Our management team has been
augmented by four new hires this year:
Daniel V. Leff, Ph.D., Daniel B. Wolfe, Ph.D., Sandra A. Matrick,
J.D., and Jody Paprin. Daniel Leff
serves us as an Executive Vice President and, as a Managing Director, as one
of our four decision-makers with respect to our investments. He has opened our first branch office, in |
||||
|
||||
Events during the quarter
included a follow-on offering of 3,450,000 of our common shares, underwritten
by Think Equity Partners LLC and Punk, Ziegel & Company, which was priced
on June 30, 2004. This oversubscribed
offering was purchased at $11.25 per share, primarily by institutional
investors. In addition to augmenting
our capital, we are hopeful that this offering will broaden our institutional
investor base, a process that has been underway since December of 2003, when
Punk, Ziegel & Company underwrote a 2,300,000 share offering of our
shares at $8.00 a share, an offering that also was oversubscribed and
purchased primarily by institutional investors. |
||||
|
||||
In spite of a weak environment
for initial public offerings (IPOs) in the context of a deteriorating stock
market, our largest portfolio holding, NeuroMetrix, Inc. (Nasdaq: NURO), had a successful IPO of 3,450,000 shares
of common stock at $8.00 per share.
Punk, Ziegel & Company and WR Hambrecht & Co. managed this
oversubscribed underwriting, which was priced on July 22, 2004. NeuroMetrix was the last of our significant,
non-tiny technology holdings. Now that
NeuroMetrix is publicly held, approximately 94 percent of our private equity
portfolio is invested in tiny technology.
The fact that NeuroMetrix is now publicly held adds to our eventual
ability to finance our growth internally:
we own 1,137,570 shares of NURO.
Although we do not anticipate at this time that, even after our
lock-up expires in January of 2005, we will be in a hurry to sell our
interest in NeuroMetrix, this holding will
eventually provide us with additional financial resources for tiny technology
investments. In the six months ended
June 30, NeuroMetrix's revenues increased by 97 percent to $7,326,282, and
its gross margin on sales increased from 70 percent to 72.7 percent. One of the primary benefits of our status
as a publicly held venture capital company is that we have permanent capital
and can be a very patient investor, even after a portfolio company completes
an IPO. |
||||
|
||||
New and follow-on investments
since the beginning of the second quarter totaled $4,026,499. Altogether, of the $16,631,962, net of
expenses and commissions, that we garnered from our follow-on offering of
shares last December, we have to date invested or used for operating expenses
all but some $3.5 million. |
||||
|
||||
Our new investments since the
beginning of the second quarter include a $250,000 investment in privately-held
Starfire Systems, Inc., and a $1,000,000 investment in CSwitch
Corporation. Starfire Systems offers a
family of patented silicon carbide forming polymers for the manufacture of
advanced ceramic materials applications.
Starfire Systems has targeted applications in aerospace, power
generation and microelectronics.
Harris & Harris Group is the first venture capital firm to invest
in Starfire Systems. Privately held
CSwitch is developing next-generation system-on-a-chip (SOC) solutions for a
wide range of communications-based platforms.
CSwitch raised $11 million in first-round financing from a group of
investors that includes ATA Ventures (www.ataventures.com), Bay Partners
(www.baypartners.com) and Charles River Ventures (www.charlesriverventures.com),
as well as Harris & Harris Group. |
||||
|
||||
Our follow-on investments
since the beginning of the second quarter include $150,000 in Nanopharma
Corp., $225,372 in Agile Materials & Technologies, Inc., $1,000,000 in
NanoGram Corporation, $401,536 in Optiva, Inc. and $887,500 in NanoOpto
Corporation. |
||||
|
||||
We are pleased that our stock
is now much more widely held by institutional investors. The commencement of the trading of listed
options of our shares on the CBOE probably has added to the liquidity of the
market in our shares on Nasdaq as well.
Our Company's growing stock market capitalization was reflected in our
recent inclusion in the Russell 2000 index, an index that includes the
smallest 2000 securities in the Russell 3000. |
||||
|
||||
The steady decline of
technology stocks since February of this year has not excepted
the price of our common stock, and market conditions were cited by one of our
portfolio companies, Nanosys, Inc., when it recently withdrew its IPO. But it is an ill wind that blows no good. If we had to chose between an open IPO
window now or one in two or three years, when we are likely to be more fully
invested and to have more companies in our portfolio that are potential IPOs,
we would certainly choose the latter timing.
It would be nice if the IPO window were open all of the time, but
realistically, as we all know, the capital markets do not operate that
way. In the meantime, we thank our
shareholders for their support as we build our Company and our portfolio of
tiny technology companies. We are
trying to be in the best position that we can be when the IPO window does
open more widely. |
||||
|
||||
|
||||
Charles E. Harris |
Mel P. Melsheimer |
Daniel V. Leff |
Douglas W. Jamison |
|
Chairman and CEO/ |
President & COO/ |
Executive Vice President/ |
Vice President/ |
|
Managing Director |
Managing Director |
Managing Director |
Managing Director |
|
|
||||
August 24, 2004 |
||||
|
||||
This
letter may contain statements of a forward-looking nature relating to future
events. These forward-looking
statements are subject to the inherent uncertainties in predicting future
results and conditions. These
statements reflect the Company's current beliefs, and a number of important
factors could cause actual results to differ materially from those expressed
in this letter. Please see the
Company's Annual Report on Form 10-K and recent Prospectus filed with the
Securities and Exchange Commission for a more detailed discussion of the
risks and uncertainties associated with the Company’s business, including but
not limited to the risks and uncertainties associated with venture capital
investing and other significant factors that could affect the Company's
actual results. Except as otherwise
required by Federal securities laws, Harris & Harris Group, Inc. undertakes
no obligation to update or revise these forward-looking statements to reflect
new events or uncertainties. |
|
|
||||||||||||
|
Unaudited Schedule of Investments* |
||||||||||||
|
(As of June 30, 2004) |
||||||||||||
|
|
||||||||||||
|
Shares/ |
|
|
||||||||||
|
Principal |
Value |
|
||||||||||
|
Investment
|
|
|
|
|||||||||
|
Agile
Materials & Technologies, Inc |
|
|
|
|||||||||
|
Series
A Convertible Preferred Stock |
3,732,736 |
$ 110,700 |
|
|||||||||
|
|
$225,603 |
229,173 |
|
|||||||||
|
|
|
339,873 |
|
|||||||||
|
|
|
|
|
|||||||||
|
AlphaSimplex Group, LLC |
|
|
|
|||||||||
|
Limited
Liability Company Interest |
-- |
125,000 |
|
|||||||||
|
|
|
|
|
|||||||||
|
Chlorogen, Inc. |
|
|
|
|||||||||
|
Series
A Convertible Preferred |
4,478,038 |
785,000 |
|
|||||||||
|
|
|
|
|
|||||||||
|
Continuum Photonics, Inc. |
|
|
|
|||||||||
|
Series
B Convertible Preferred Stock |
2,000,000 |
776,119 |
|
|||||||||
|
Series
C Convertible Preferred Stock |
2,689,103 |
839,000 |
|
|||||||||
|
|
|
1,615,119 |
|
|||||||||
|
|
|
|
|
|||||||||
|
CSwitch, Inc. |
|
|
|
|||||||||
|
Series
A Convertible Preferred Stock |
1,000,000 |
1,000,000 |
|
|||||||||
|
|
|
|
|
|||||||||
|
Experion
Systems, Inc. |
|
|
|
|||||||||
|
Series
A Convertible Preferred Stock |
294,118 |
262,406 |
|
|||||||||
|
Series
B Convertible Preferred Stock |
35,294 |
31,226 |
|
|||||||||
|
Series
C Convertible Preferred Stock |
222,184 |
417,706 |
|
|||||||||
|
Series
D Convertible Preferred Stock |
64,501 |
121,
262 |
|
|||||||||
|
|
|
832,600 |
|
|||||||||
|
|
|
|
|
|||||||||
|
Exponential Business
Development Company |
|
|
|
|||||||||
|
Limited
Partnership Interest |
-- |
25,000 |
|
|||||||||
|
|
|
|
|
|||||||||
|
Heartware, Inc. |
|
|
|
|||||||||
|
Series
A-2 Non-Voting Preferred Stock |
47,620 |
0 |
|
|||||||||
|
|
|
|
|
|||||||||
|
Molecular Imprints, Inc. |
|
|
|
|||||||||
|
Series
B Convertible Preferred Stock |
1,333,333 |
2,000,000 |
|
|||||||||
|
|
|
|
|
|||||||||
|
NanoGram Corporation |
|
|
|
|||||||||
|
Series
I Convertible Preferred Stock |
63,210 |
21,672 |
|
|||||||||
|
Series
II Convertible Preferred Stock |
1,250,904 |
1,000,723 |
|
|||||||||
|
|
|
1,022,395 |
|
|||||||||
|
|
|
|
|
|||||||||
|
NanoOpto Corporation |
|
|
|
|||||||||
|
Series
A-1Convertible Preferred Stock |
267,857 |
47,567 |
|
|||||||||
|
Series
B Convertible Preferred Stock |
1,733,664 |
737,500 |
|
|||||||||
|
|
|
785,067 |
|
|||||||||
|
|
|
|
|
|||||||||
|
Nanopharma Corp. |
|
|
|
|||||||||
|
Series
A Convertible Preferred Stock |
684,516 |
700,000 |
|
|||||||||
|
Subordinated
|
$150,000 |
151,479 |
|
|||||||||
|
|
|
851,479 |
|
|||||||||
|
|
|
|
|
|||||||||
|
Nanosys, Inc. |
|
|
|
|||||||||
|
Series
C Convertible Preferred Stock |
803,428 |
1,500,000 |
|
|||||||||
|
|
|
|
|
|||||||||
|
Nanotechnologies, Inc. |
|
|
|
|||||||||
|
Series
B Convertible Preferred Stock |
1,538,837 |
553,982 |
|
|||||||||
|
Series
C Convertible Preferred Stock |
235,720 |
84,859 |
|
|||||||||
|
|
|
638,841 |
|
|||||||||
|
|
|
|
|
|||||||||
|
Nantero, Inc. |
|
|
|
|||||||||
|
Series
A Convertible Preferred Stock |
345,070 |
538,309 |
|
|||||||||
|
Series
B Convertible Preferred Stock |
207,051 |
323,000 |
|
|||||||||
|
|
|
861,309 |
|
|||||||||
|
|
|
|
|
|||||||||
|
NeoPhotonics
Corporation |
|
|
|
|||||||||
|
Common
Stock |
60,580 |
9,105 |
|
|||||||||
|
Series
1 Convertible Preferred Stock |
1,831,256 |
2,014,677 |
|
|||||||||
|
Warrants
at $0.15 expiring 3/12/11 |
30,426 |
304 |
|
|||||||||
|
|
|
2,024,086 |
|
|||||||||
|
|
|
|
|
|||||||||
|
NeuroMetrix, Inc. |
|
|
|
|||||||||
|
Series
A Convertible Preferred Stock |
875,000 |
1,312,500 |
|
|||||||||
|
Series
B Convertible Preferred Stock |
625,000 |
937,500 |
|
|||||||||
|
Series
C-2 Convertible Preferred Stock |
1,148,100 |
1,722,150 |
|
|||||||||
|
Series
E Convertible Preferred Stock |
499,996 |
749,994 |
|
|||||||||
|
Series
E-1 Convertible Preferred Stock |
1,402,187 |
2,103,282 |
|
|||||||||
|
|
|
6,825,426 |
|
|||||||||
|
|
|
|
|
|||||||||
|
Optiva, Inc. |
|
|
|
|||||||||
|
Series
C Convertible Preferred Stock |
1,249,999 |
625,000 |
|
|||||||||
|
|
|
|
|
|||||||||
|
Questech Corporation |
|
|
|
|||||||||
|
Common
Stock |
646,954 |
724,588 |
|
|||||||||
|
Warrants
at $5.00 expiring 10/25/04 |
1,966 |
0 |
|
|||||||||
|
Warrants
at $1.50 expiring 11/16/05 |
1,250 |
0 |
|
|||||||||
|
Warrants
at $1.50 expiring 08/03/06 |
8,500 |
0 |
|
|||||||||
|
Warrants
at $1.50 expiring 11/21/07 |
3,750 |
0 |
|
|||||||||
|
Warrants
at $1.50 expiring 11/19/08 |
|
5,000 |
|
|||||||||
|
|
|
0 |
|
|||||||||
|
|
|
724,588 |
|
|||||||||
|
Starfire Systems, Inc. |
|
|
|
|||||||||
|
Common
Stock |
125,000 |
50,000 |
|
|||||||||
|
Series
A-1 Convertible Preferred Stock |
200,000 |
200,000 |
|